Annovis, Inc.
34 Mount Pleasant Drive
Aston
Pennsylvania
19014
United States
Tel: 610-579-1200
Fax: 610-579-1201
Website: http://www.annovis.com/
Email: info@annovis.com
17 articles about Annovis, Inc.
-
While donanemab showed impressive results in Phase III TRAILBLAZER-ALZ 2, concerns regarding its safety remain compared with Biogen’s and Eisai’s Leqembi.
-
Annovis Bio Announces Issuance of U.S. Patent Covering the Use of Lead Drug Candidate, Buntanetap, for Prevention or Treatment of Disease States Due to Metal Dis-Homeostasis in Healthy or Sick Humans
4/27/2023
Annovis Bio announced that the United States Patent and Trademark Office has granted the Company a patent with claims covering the use of Annovis Bio’s lead drug candidate, buntanetap, for the prevention and treatment of diseases caused by the disruption in heavy metal homeostasis.
-
Research hasn't shown that removing amyloid plaques alone improves function in Alzheimer's patients, said Sharon L. Rogers, CEO of AmyriAD.
-
Biogen and Eisai's lecanemab win this week provides an opportunity to stop and consider whether science is closer to a cure or symptom management for Alzheimer's disease.
-
If the FDA ultimately votes to approve Eli Lilly’s donanemab or Eisai’s lecanemab – both anti-amyloid beta (Aβ) antibodies – what impact will it make on Alzheimer’s disease?
-
Intercept Pharmaceuticals, Annovis Bio and Biohaven Pharma are moving forward with late-stage Phase III clinical trials.
-
Annovis Bio Submits an International Patent Application to Cover the Treatment of Neurological Injuries Caused by Infections
6/9/2022
Annovis Bio's Current Intellectual Property Portfolio Covers the Use of Buntanetap, the Company's Lead Compound, to Treat Neurodegenerative Diseases.
-
BioSpace Movers & Shakers, Jan. 14
1/14/2022
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Annovis Bio Announces Transfer of Listing to the New York Stock Exchange
11/15/2021
The Company's common stock will begin trading under the symbol "ANVS" at the opening of trading on November 18, 2021.
-
The Annual Biomarkers for Alzheimer’s Disease Summit is running from August 25-26. Here’s a look at some of the top stories from day one.
-
Annovis Bio, Inc. to present at the Q1 Virtual Investor Summit
3/11/2021
Annovis Bio, Inc., ANVS, today announced that Maria Maccecchini, PhD, Founder, President and CEO, will be attending the Q1 Virtual Investor Summit. Event Q1 Investor Summit Date March 23-25th, 2021 Presentation March 24th @ 11:30AM ET
-
Annovis Bio to Present at Benzinga Global Small Cap Conference on December 8, 2020
12/7/2020
Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced its CEO, Maria Maccecchini, Ph.D., will present at Benzinga's inaugural Global SmallCap Conference on Tuesday, December 8, 2020 at 4:30 pm ET. Investors interested in viewing Annovis Bio's presentation may register with free access here for the two-day
-
Annovis Bio to Participate in A.G.P.'s Virtual Healthcare Symposium
11/16/2020
Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced its CEO, Maria Maccecchini, Ph.D. and CFO, Jeff McGroarty, MBA, CPA, will participate in A.G.P.'s Virtual Healthcare Symposium on Thursday, November 19, 2020. Dr. Maccecchini and Mr. McGroarty will host virtual one-on-one meetings with investors to disc
-
Annovis Bio Resumes Treatment of Patients in Ongoing Phase 2a Study in Alzheimer’s Disease after COVID-Related Delay
10/29/2020
Annovis Bio Inc., a clinical-stage drug platform company addressing Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases, announced it resumed treatment of patients in its Phase 2a clinical trial in early AD patients following the suspension of the trial in March 2020 due to COVID-19.
-
Annovis Bio to Present at the 2020 BIO Investor Forum
10/12/2020
Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced that Maria Maccecchini, Ph.D., Founder and Chief Executive Officer, will present at the 2020 BIO Investor Forum, which will be held in a digital format October 13-15, 2020. The company presentation will be available on demand during the virtual event for a
-
Annovis Bio CEO Appears on Executive Leaders Radio Program
7/23/2020
Annovis Bio Inc., a clinical-stage drug platform company addressing Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases, announced its CEO, Maria Maccecchini, Ph.D., will appear on the Executive Leaders Radio program, airing nationally on Radio America on July 26, 2020 at 11 a.m.
-
Annovis Bio 2020 Annual Meeting of Stockholders to Be Held on June 3, 2020
6/1/2020
Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, will hold its 2020 Annual Meeting of Stockholders in a virtual meeting format on Wednesday, June 3, 2020 at 10:00 a.m. (Eastern Time) at www.viewproxy.com/AnnovisBio/2020/VM . Shareholders of record that attend the Annual Meeting will be able to vote and submit ques